Silver Book Fact

Imatinib, the first chemical agent to target a cancer-specific protein, improved 5-year survival rates for chromosome-positive chronic myelogenous leukemia (CML) from 17% in the mid-1970s to 63% in 2007.

SEER Stat Fact Sheets: Chronic myeloid leukemia (CML). http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed November 5, 2015

American Association for Cancer Research. AACR Cancer Progress Report 2015: Transforming lives through precision medicine. Clin Cancer Res. 2015; 21(S1). http://cancerprogressreport.org/Pages/default.aspx

Reference

Title
SEER Stat Fact Sheets: Chronic myeloid leukemia (CML)
Authors
Surveillance, Epidemiology, and End Results Program (SEER)
URL
Read Full Resource
Title
AACR Cancer Progress Report 2015: Transforming lives through precision medicine
Publication
Clin Cancer Res
Publication Date
2015
Authors
American Association for Cancer Research
Volume & Issue
Volume 21, Issue S1
Pages
S1-128
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • 750 cancer-fighting medicines are currently in development.  
  • A drug for testicular cancer that cost an estimated $56 million to develop led to a sharp increase in survival rate and an annual return of $166 million in treatment…  
  • Use of tamoxifen, a drug used to treat breast cancer, has resulted in a direct cost savings of $41,372 per year of life gained in women 35- to 49-years-old, $68,349…